Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The observational study titled ‘Finerenone Research of Outcomes and Drug Utilization’ (FINEROD) by Bayer AG aims to assess the real-world use, safety, and efficacy of finerenone in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). This study is significant as it seeks to gather comprehensive data on finerenone’s impact on kidney and heart health in these patients.
Finerenone, a drug that blocks mineralocorticoid receptors, is being tested for its ability to reduce kidney, heart, and blood vessel damage in CKD and T2D patients. It is already approved in the US and prescribed by doctors.
The study is observational, using a cohort model with a retrospective time perspective. It collects data from commercial electronic health records and national claims in the US and Asia, focusing on patients already receiving finerenone as part of their routine care.
The study began on May 15, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 4, 2025, indicating ongoing data collection and analysis.
This study could influence Bayer’s stock performance by providing insights into finerenone’s market potential and safety profile, potentially affecting investor sentiment. Competitors in the CKD and T2D treatment space may also be impacted by these findings.
The study is currently recruiting, with further details available on the ClinicalTrials portal.